OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel: Oxford, UK Wednesday, November 12, 2025, 17:00 Hrs [IST] Oxford Gene Technology (OGT), a Sysmex ...
Title: GB3226, A Novel, Orally Active, First-in-Class Small Molecule Inhibitor of ENL-Yeats and FLT3 Kinase for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Presenting Author: Louis ...
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback